Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases 22,189 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 22,189 shares of the stock in a transaction dated Monday, March 31st. The shares were bought at an average price of $17.46 per share, with a total value of $387,419.94. Following the completion of the purchase, the insider now directly owns 12,455,264 shares of the company’s stock, valued at approximately $217,468,909.44. This trade represents a 0.18 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, April 2nd, Broadwood Partners, L.P. bought 31,780 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.43 per share, with a total value of $553,925.40.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was acquired at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were bought at an average price of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The shares were bought at an average cost of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was bought at an average cost of $21.50 per share, with a total value of $176,751.50.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock opened at $17.60 on Thursday. The stock has a market capitalization of $868.12 million, a P/E ratio of -42.93 and a beta of 0.66. The business has a 50 day simple moving average of $19.12 and a two-hundred day simple moving average of $24.92. STAAR Surgical has a 12 month low of $13.50 and a 12 month high of $52.68.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on STAA. Stephens reaffirmed an “equal weight” rating and set a $17.00 target price on shares of STAAR Surgical in a report on Tuesday, March 18th. William Blair cut shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Jefferies Financial Group lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Canaccord Genuity Group cut their price target on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Finally, BTIG Research downgraded STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, STAAR Surgical presently has an average rating of “Hold” and a consensus price target of $25.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STAA. Quarry LP purchased a new stake in shares of STAAR Surgical during the third quarter worth $50,000. KLP Kapitalforvaltning AS acquired a new position in shares of STAAR Surgical during the 4th quarter worth approximately $180,000. Bridgefront Capital LLC increased its holdings in shares of STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 2,306 shares during the last quarter. FMR LLC boosted its stake in STAAR Surgical by 79.3% during the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after buying an additional 3,136 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in STAAR Surgical during the fourth quarter worth $278,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.